Referent:innen

Dr Rainer Gnibl

Dr Rainer Gnibl

GMP Inspector

Dr. Sabine Hauck

Dr. Sabine Hauck

dequra pharma consult hauck, Chair of ECA ATMP Interest Group

Dr. Katja Aschermann

Dr. Katja Aschermann

TETEC

Dr. Wolfgang Schumacher

Dr. Wolfgang Schumacher

formerly F. Hoffmann-La Roche

Kati Kebbel

Kati Kebbel

Fraunhofer-Institut für Zelltherapie und Immunologie IZI

Mag. Gabriela Schallmeiner

Mag. Gabriela Schallmeiner

Inspection Ready Consulting, Austrian Qualified Person Association (aqpa)

Zielsetzung

As part of this GMP course for ATMPs (Advanced Therapy Medicinal Products), you will learn about the existing regulatory requirements for aseptic manufacturing, CCS, data integrity, lyophilisation according to the new Annex 1 and much more from various experts from authorities, industry and consulting. In addition to the GMP requirements, you will also learn about the impact and implementation of the new Annex 1.

Hintergrund

The new Annex 1 is in effect and must now be implemented. The correct interpretation and implementation in daily business is often difficult and raises many questions. Compliance with the GMP regulations is essential for the continuous, traceable and high-quality manufacture, testing and control of pharmaceutical products.

Advanced Therapy Medicinal Products (ATMPs) are a group of innovative and sophisticated medical treatments that use advanced technologies to modify or use living cells, tissues or genes for therapeutic purposes. These therapies focus on targeting the underlying causes of disease at the cellular and genetic level, with the aim of treating, preventing or diagnosing diseases. ATMPs include gene therapies, cell therapies and tissue engineered products and represent a significant step in medical treatments.

New ATMPs with innovative properties are constantly being developed. It does not matter whether it is a personalized product, production or even transport. The ultimate goal always remains a safe and effective product that provides the patient with healing or relief without harming them. To ensure this, employees must comply with the current regulations. This course offers deeper insights into the regulations and advice on implementing the new and existing requirements of ATMPs.
 

Zielgruppe

This training is aimed at employees from quality assurance, quality control and production who have daily contact with ATMPs and have to work according to the existing GMP requirements. Experienced staff will have the opportunity to extend and deepen their existing knowledge in core aspects of GMP and Annex 1 Areas.

Presentations/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.

Programm

Advanced GMP for ATMPs

Gesamtes Programm als PDF herunterladen

EU-GMP Guideline Part IV: Overview
Dr Rainer Gnibl
  •  Positioning within EudraLex Vol. 4
  •  Definition of ATMPs
  •  Document structure & technical content
  •  Key messages
Quality Risk Management for ATMPs
Dr Rainer Gnibl
  •  What does QRM mean?
  •  ICH Q9 Quality Risk Management (Overview)
  •  Bounderies & Limitations
  •  Examples from Guideline
Freeze-drying of Vectors in the Light of Update Annex 1
Dr Sabine Hauck
  •  Annex 1 requirements for lyophilization
  •  Further regulatory requirements for (non-)viral vectors
  •  Benefits of freeze-dried viral vector formulations
Aseptic Manufacturing of Cell-based ATMPs (HCGTP)
Dr Katja Aschermann
  •  Challenges
  •  Impact of new Annex 1
  •  Cross Contamination Control Strategy
Environmental Monitoring
Dr Rainer Gnibl
  •  Segregation between Classification, Qualification & Monitoring
  •  Clean room lifecycle
  •  Monitoring elements
  •  Personell & clean room monitoring
Data Integrity of Automated, Decentralised Cell Therapy Production
Dr Wolfgang Schumacher
  •  DI concept in research-oriented smaller companies
  •  Computer-assisted manufacturing of therapeutics
  •  DI issues in testing, release and logistics 
  •  DI questions in the context of inspections
Contamination Control Strategy
Dr Katja Aschermann
  •  Definition
  •  Creation of a CCS
  •  Selected items
Qualification and Validation – a Versatile and Efficient Quality Tool in the ATMP Manufacturing
Kati Kebbel
  • Clarification of types of qualification and validation applied in ATMP manufacturing
    - supplier qualification
    - device qualification
    - software validation
  •  (Aseptic) process qualification / Validation
    - method Validation
    - operator qualification
  • Regulatory basis
  • How are these types used in the ATMP manufacturing - described in a case study for a clinical phase I/II ATMP
ATMPs a Challenge for Quality Control
Dr Katja Aschermann
  • From product to control strategy via CQAs
  • Measurement of quality attributes
  • Specifications
  • Stability
  • Validation
Regulatory Landscape - Opportunities and Challenges
Gabriela Schallmeiner
  • Overview for ATMPs
  • Specific requirements for ATMPs - opportunities and challenges
  • Examples on points to consider in CMC
If the Guidelines become a Challenge
Kati Kebbel
  • Media Growth Promotion Test according to EP 2.6.1 vs. 2.6.27 and impact to sterility method validation
  • APS challenges
  • Change of standard APS strategy - a future Vision?
Batch Release - What to Consider for AT(I)MPs
Gabriela Schallmeiner
  •  EU Regulatory framework
  •  GMP for AT(I)MPs
  •  QP batch certifcation

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar
icon
Aufzeichnung nicht verfügbar

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular